secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-022837
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA reports Q3 net income $1.6M; cash $393.9M; darovasertib registrational trial planned Q1 2023
--------------------------------------------------------------------------------

- Cash equivalents and marketable securities of $393.9M as of Sep 30, 2022, sufficient into 2026.
- Q3 net income of $1.6M vs. Q2 net loss of $22.1M; collaboration revenue $29.7M (up from $5.9M).
- Targeting initiation of potential registrational trial for darovasertib + crizotinib in MUM in Q1 2023.
- Initiated IDE397 Phase 2 monotherapy expansion and combination dose escalation with pemetrexed/taxanes.
- Targeting IND for PARG inhibitor IDE161 in Q4 2022 and Pol Theta Helicase FIH study in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017022022837/0000950170-22-022837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017022022837/idya-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer